Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
View Patent ↗The present invention provides compositions and methods for reducing hypoglycemic episodes experienced by a subject in need of treatment for diabetes mellitus, said method comprising orally administering an amount of an insulin polypeptide-oligomer conjugate to the subject, wherein: i) the amount of the insulin polypeptide-oligomer conjugate reduces the number and/or severity of hypoglycemic episodes experienced by the subject during a given time period when compared with the number and/or severity of hypoglycemic episodes that would have been experienced during a similar time period by the subject or by subjects in a control group parenterally administered insulin or an insulin analog in an amount that provides a substantially equivalent level of glycemic control; and ii) the oligomer of the insulin polypeptide-oligomer conjugate comprises a hydrophilic moiety and a lipophilic moiety.
1. A method for reducing hypoglycemic episodes experienced by a human subject in need of treatment for diabetes mellitus and having a tendency toward hypoglycemic episodes, said method comprising:
orally administering an amount of an insulin polypeptide-oligomer conjugate to the human subject, wherein the insulin polypeptide-oligomer conjugate comprises an insulin polypeptide and an oligomer, wherein the oligomer comprises a hydrophilic moiety and a lipophilic moiety, wherein the insulin polypeptide-oligomer conjugate is a mono-conjugate, wherein the oligomer is coupled to an amino functionality of insulin at Lys B-29 , and wherein the amount of the insulin polypeptide-oligomer conjugate orally administered to the subject maintains the subject's blood glucose level between 80 mg/dl and 250 mg/dl and reduces the number and/or severity of hypoglycemic episodes experienced by the human subject during a given time period when compared with the number and/or severity of hypoglycemic episodes that would have been experienced during a similar time period by the human subject parenterally administered insulin or an insulin analog in an amount that provides a substantially equivalent level of glycemic control.
2. The method of claim 1 , wherein the amount of the insulin polypeptide oligomer conjugate orally administered to the subject is between 0.05 and 5 mg per kilogram body weight.
3. The method of claim 1 , wherein the amount of insulin polypeptide-oligomer conjugate orally administered to the subject reduces the number of hypoglycemic episodes experienced by the subject.
4. The method of claim 1 , wherein the amount of insulin polypeptide-oligomer conjugate orally administered to the subject reduces the severity of hypoglycemic episodes experienced by the subject.
5. The method of claim 1 , wherein the insulin polypeptide of the insulin polypeptide-oligomer conjugate comprises:
a lysine at B-29;
an A chain having an N terminus;
a B chain having an N terminus; and
wherein the oligomer of the insulin polypeptide-oligomer conjugate is coupled to the lysine at B-29.
6. The method of claim 1 , wherein the hydrophilic moiety is a polyalkylene glycol moiety.
7. The method of claim 1 , wherein the lipophilic moiety is an alkyl or fatty acid moiety.
8. The method of claim 1 , wherein the insulin polypeptide-oligomer conjugate comprises the structure of Formula V:
9. The method of claim 1 , wherein the amount of the insulin polypeptide-oligomer conjugate orally administered to the subject maintains the subject's blood glucose level between 70 mg/dl and 120 mg/dl when measured before a meal.
10. The method of claim 1 , wherein the amount of the insulin polypeptide-oligomer conjugate orally administered to the subject maintains the subject's blood glucose level at less than 180 mg/dl but more than 70 mg/dl when measured within two hours after a meal.